1. Pink Sheet

Parallel Advice: A False Step in March to Globalized New Drug Reviews?

 
• By Kate Rawson

Few manufacturers are taking advantage of a program under which FDA and European regulators work together to provide scientific advice to drug developers. Now the agency is wondering whether it should end the program.

By Kate Rawson

For drug companies pursuing a global product development plan, nothing is more frustrating than receiving different

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D